| Code | CSB-RA006163MB9HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Gotistobart, targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA4), a critical immune checkpoint receptor expressed on T cells. CTLA4 functions as a negative regulator of T-cell activation by competing with the costimulatory receptor CD28 for binding to B7 ligands (CD80/CD86) on antigen-presenting cells. By delivering inhibitory signals, CTLA4 maintains immune homeostasis and prevents excessive T-cell responses. Dysregulation of CTLA4-mediated immune suppression is implicated in autoimmune diseases and plays a significant role in tumor immune evasion, making it a valuable target for immunological research.
Gotistobart is a therapeutic monoclonal antibody developed to modulate CTLA4 activity in immune-related conditions. This biosimilar antibody provides researchers with a reliable tool for investigating CTLA4 biology, exploring immune checkpoint mechanisms, and studying T-cell regulation in various disease models. It supports investigations into autoimmunity, transplantation immunology, and cancer immunotherapy research, enabling detailed analysis of CTLA4's role in immune modulation.
There are currently no reviews for this product.